A biomarker catalog for inflammatory bowel disease medications
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Introduction: Inflammatory bowel disease (IBD), which includes Crohns disease (CD) and ulcerative colitis (UC), is a multifaceted illness with diverse manifestations. Current treatment strategies are inadequate, with low response rates, secondary loss of response, and serious side effects. Methods: We leveraged a large multiomics dataset (SPARC IBD) to compile a catalog of biomarkers for (i) disease severity, (ii) medication use, and (iii) response to a medication. Data were stratified based on IBD subtype (UC and CD) and tissue type; biomarker associations were identified using mixed-effects models to account for multiple medication groups, disease status (e.g., remission, active, etc.), and repeated sampling. Results: Our catalog lists thousands of potential biomarkers for disease severity (9,657), medication effect (293), and medication response (59). These biomarkers, both known and novel, span multiple diagnoses, tissues, and medications. Conclusion: These therapy-specific signatures will enable tracking of treatment response, diagnosis of disease severity, and identification of new therapeutic targets.
